Quintiles has been chosen as a preferred provider by Bristol-Myers Squibb Company (BMY) to provide global support for Bristol-Myers Squibb’s central lab work, biomarker testing and assay development for the next five years.

“This agreement deepens the commitment our companies share to providing patients access to effective, safe and affordable treatments,” said Thomas Wollman, senior vice president of Quintiles Global Laboratories. “We look forward to working with Bristol-Myers Squibb to bring personalized medicine into mainstream drug development.”